Compare ADMA Biologics Inc (ADMA) vs Emerson Electric Co. (EMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Emerson Electric Co. — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Emerson Electric Co. trades at $135.65 (market cap $77.24B). The key difference: Emerson Electric Co. is far larger — about 36.3× ADMA Biologics Inc's market cap, and Emerson Electric Co. pays a 1.61% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EMR | |
|---|---|---|
Market Cap | $2.13B | $77.24B |
Sector | Health | Industrials |
52-Week High | $20.38 | $161.69 |
52-Week Low | $7.60 | $123.30 |
Enterprise Value | $2.20B | $89.51B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Emerson Electric (EMR) trades at $137.91, down 0.82% on the day, with a neutral technical signal and mixed earnings history. The company maintains solid profitability with a 52.67% gross margin and 13.35% net margin, though ROE is modest at 3.05%. Recent news highlights collaboration with Aramco on corrosion R&D and positive momentum in its Intelligent Devices segment, while cash flow trends show volatility with a net outflow of $2.04B in 2025.
The outlook is cautiously optimistic, supported by a majority analyst buy rating and a $157.60 consensus price target implying 14% upside. Key risks include fluctuating cash flows, elevated debt levels, and competitive pressures in the industrial automation sector. Earnings growth and segment execution remain critical for sustained stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
